Pacylex Pharmaceuticals is the world leader in the clinical development of NMT inhibition therapy for cancer with multiple Phase 2a programs underway. Myristoylation is a post-translational modification facilitating membrane association of proteins essential for many cancer processes such as pro-survival and proliferation signaling, energy production, receptor translocation and angiogenesis. Pharma and Venture investors have taken an interest in NMT inhibitors as ADC payloads and Pacylex has exclusive license to a family of small molecule inhibitors of N-myristoyl transferases (NMTi) as potential ADC payloads. Pacyles is developing one, zelenirstat, a first-in-class myristoylation inhibitor, as an oral daily therapy for cancer. Zelenirstat has good long term systemic toxicity, Phase 1 activity in multiple types of solid tumor cancers and lymphoma and is now in phase 2a studies in heme and solid tumor cancers. Pacylex is seeking ADC partners and partners and investors for oral zelenirstat development.